RU2011131532A - Способ лечения бессонницы - Google Patents
Способ лечения бессонницы Download PDFInfo
- Publication number
- RU2011131532A RU2011131532A RU2011131532/15A RU2011131532A RU2011131532A RU 2011131532 A RU2011131532 A RU 2011131532A RU 2011131532/15 A RU2011131532/15 A RU 2011131532/15A RU 2011131532 A RU2011131532 A RU 2011131532A RU 2011131532 A RU2011131532 A RU 2011131532A
- Authority
- RU
- Russia
- Prior art keywords
- melatonin
- drug
- medicament
- release composition
- sustained release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
1. Применение мелатонина, перорально в композиции с замедленным высвобождением, в производстве лекарственного средства для лечения субъективно оцененного нересторативного сна у пациентов, страдающих первичной бессонницей, по определению DSM-IV, в котором указанное лекарственное средство включает также, по меньшей мере, один фармацевтически приемлемый разбавитель, консервант, антиоксидант, растворитель, эмульгатор, адъювант или носитель, в котором указанный мелатонин присутствует в указанном лекарственном средстве при эффективном количестве в пределах от 0,0025 до 50 мг.2. Использование по п.1, при котором лекарственное средство представлено в единичной дозированной форме, а каждая единичная доза содержит мелатонин в пределах 0,025-10 мг.3. Использование по п.2, при котором указанная композиция с замедленным высвобождением включает акриловую резину.4. Лекарственное средство для лечения субъективно оцененного нересторативного сна у пациентов, страдающих первичной бессонницей, по определению DSM-IV, содержащее мелатонин, в эффективных количествах в пределах от 0,0025 до 50 мг, перорально в композиции с замедленным высвобождением, и, по меньшей мере, один фармацевтически приемлемый разбавитель, консервант, антиоксидант, растворитель, эмульгатор, адъювант или носитель.5. Лекарственное средство по п.4, в котором каждая единичная доза содержит мелатонин в пределах от 0,0025 до 10 мг.6. Лекарственное средство по п.5, в котором указанная композиция с замедленным высвобождением включает акриловую резину.
Claims (6)
1. Применение мелатонина, перорально в композиции с замедленным высвобождением, в производстве лекарственного средства для лечения субъективно оцененного нересторативного сна у пациентов, страдающих первичной бессонницей, по определению DSM-IV, в котором указанное лекарственное средство включает также, по меньшей мере, один фармацевтически приемлемый разбавитель, консервант, антиоксидант, растворитель, эмульгатор, адъювант или носитель, в котором указанный мелатонин присутствует в указанном лекарственном средстве при эффективном количестве в пределах от 0,0025 до 50 мг.
2. Использование по п.1, при котором лекарственное средство представлено в единичной дозированной форме, а каждая единичная доза содержит мелатонин в пределах 0,025-10 мг.
3. Использование по п.2, при котором указанная композиция с замедленным высвобождением включает акриловую резину.
4. Лекарственное средство для лечения субъективно оцененного нересторативного сна у пациентов, страдающих первичной бессонницей, по определению DSM-IV, содержащее мелатонин, в эффективных количествах в пределах от 0,0025 до 50 мг, перорально в композиции с замедленным высвобождением, и, по меньшей мере, один фармацевтически приемлемый разбавитель, консервант, антиоксидант, растворитель, эмульгатор, адъювант или носитель.
5. Лекарственное средство по п.4, в котором каждая единичная доза содержит мелатонин в пределах от 0,0025 до 10 мг.
6. Лекарственное средство по п.5, в котором указанная композиция с замедленным высвобождением включает акриловую резину.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL144900 | 2001-08-14 | ||
IL144900A IL144900A (en) | 2001-08-14 | 2001-08-14 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
PCT/IL2002/000662 WO2003015690A2 (en) | 2001-08-14 | 2002-08-12 | Method for treating primary insomnia |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011131532A true RU2011131532A (ru) | 2013-03-27 |
RU2560840C2 RU2560840C2 (ru) | 2015-08-20 |
Family
ID=11075696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011131532/15A RU2560840C2 (ru) | 2001-08-14 | 2002-08-12 | Способ лечения бессонницы |
Country Status (35)
Country | Link |
---|---|
US (1) | US8962024B2 (ru) |
EP (2) | EP1441702B1 (ru) |
JP (1) | JP2005501095A (ru) |
KR (1) | KR20040032917A (ru) |
CN (1) | CN100453078C (ru) |
AR (1) | AR034975A1 (ru) |
AU (1) | AU2002326114C1 (ru) |
BR (1) | BR0211855A (ru) |
CA (1) | CA2454699C (ru) |
CL (1) | CL2002001701A1 (ru) |
CR (1) | CR7271A (ru) |
CY (2) | CY1118924T1 (ru) |
DK (2) | DK3103443T3 (ru) |
EA (1) | EA200400302A1 (ru) |
ES (2) | ES2626591T3 (ru) |
GT (1) | GT200200164A (ru) |
HK (1) | HK1066161A1 (ru) |
HU (1) | HU230786B1 (ru) |
IL (1) | IL144900A (ru) |
IS (1) | IS3004B (ru) |
JO (1) | JO3446B1 (ru) |
LT (1) | LT1441702T (ru) |
MX (1) | MXPA04001372A (ru) |
NO (1) | NO334788B2 (ru) |
NZ (1) | NZ531318A (ru) |
PA (1) | PA8552301A1 (ru) |
PE (1) | PE20030331A1 (ru) |
PL (1) | PL367872A1 (ru) |
PT (2) | PT1441702T (ru) |
RU (1) | RU2560840C2 (ru) |
SI (1) | SI1441702T1 (ru) |
UA (1) | UA87262C2 (ru) |
UY (1) | UY27401A1 (ru) |
WO (1) | WO2003015690A2 (ru) |
ZA (1) | ZA200402005B (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL144900A (en) | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
US20070088079A1 (en) * | 2005-09-20 | 2007-04-19 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for sleep disorder |
AR056076A1 (es) * | 2005-09-20 | 2007-09-19 | Takeda Pharmaceutical | Agente profilactico o terapeutico para el desorden de sueno |
MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
US8940326B2 (en) | 2007-03-19 | 2015-01-27 | Vita Sciences Llc | Transdermal patch and method for delivery of vitamin B12 |
WO2008122102A1 (en) * | 2007-04-05 | 2008-10-16 | Iomedix Development International Srl | Melatonin-based composition for improved sleep |
US20080248106A1 (en) | 2007-04-05 | 2008-10-09 | Marvin Heuer | Melatonin-based composition for improved sleep |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
WO2012103411A2 (en) * | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
AU2016426598C1 (en) | 2016-10-31 | 2024-02-08 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3126375A (en) | 1964-03-24 | Chioacyl | ||
US2789118A (en) | 1956-03-30 | 1957-04-16 | American Cyanamid Co | 16-alpha oxy-belta1, 4-pregnadienes |
US2990401A (en) | 1958-06-18 | 1961-06-27 | American Cyanamid Co | 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids |
US3048581A (en) | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
US3749712A (en) | 1970-09-25 | 1973-07-31 | Sigma Tau Ind Farmaceuti | Triamcinolone acetonide esters and process for their preparation |
SE378109B (ru) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
SE378110B (ru) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US3996359A (en) | 1972-05-19 | 1976-12-07 | Ab Bofors | Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith |
EP0126630B1 (en) | 1983-05-18 | 1987-09-16 | Monash University | The use of melatonin for the manufacture of a medicament |
JPS6045513A (ja) * | 1983-05-18 | 1985-03-12 | モナシユ ユニバ−シテイ | 身体行動および機能の日周期の不調を軽減する薬剤 |
US4600723A (en) * | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
US5151446A (en) | 1989-09-25 | 1992-09-29 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5707652A (en) | 1990-12-04 | 1998-01-13 | State Of Oregon | Methods of treating circadian rhythm phase disorders |
US5591768A (en) * | 1990-12-04 | 1997-01-07 | State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Methods for treating circadian rhythm phase disturbances |
DE122007000073I1 (de) * | 1991-05-09 | 2008-01-31 | Neurim Pharma 1991 | Melatonin enthaltene Arzneimittel |
IT1251544B (it) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico |
FR2680507B1 (fr) | 1991-08-23 | 1993-10-08 | Adir Cie | Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
ATE141051T1 (de) * | 1992-04-07 | 1996-08-15 | Neurim Pharma 1991 | Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie |
US5449683A (en) | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
IL103411A (en) | 1992-10-11 | 1996-11-14 | Neurim Pharma 1991 | Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma |
AU690527B2 (en) | 1992-12-17 | 1998-04-30 | Pfizer Inc. | Pyrazoles having CRF antagonist activity |
US6765008B1 (en) | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
KR100190730B1 (ko) | 1992-12-17 | 1999-06-01 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸 |
AU7550994A (en) | 1993-07-26 | 1995-02-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Sustained release oral compositions containing melatonin |
US5654325A (en) | 1993-11-18 | 1997-08-05 | Eli Lilly And Company | Melatonin derivatives for use in treating sleep disorders |
US5403851A (en) | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
US6469044B1 (en) | 1995-02-01 | 2002-10-22 | Neurim Pharmaceuticals (1991) Ltd. | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
US5688520A (en) * | 1995-03-29 | 1997-11-18 | Minnesota Mining And Manufacturing Company | Transmucosal delivery of melatonin for prevention of migraine |
EP0748627A3 (en) | 1995-06-14 | 1997-05-21 | Lilly Co Eli | Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate |
NO981489L (no) * | 1995-10-03 | 1998-05-22 | Interneuron Pharma | Blandinger av melatonin og analgetika samt anvendelser derav |
ATE265209T1 (de) * | 1996-07-17 | 2004-05-15 | Merck & Co Inc | Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten |
US5776969A (en) | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
US5826408A (en) * | 1997-05-08 | 1998-10-27 | Riverwood International Corporation | Rotary flap tucker for a cartoning machine |
US6472421B1 (en) | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
PL201219B1 (pl) * | 2000-01-05 | 2009-03-31 | Neurim Pharma 1991 | Zastosowanie melatoniny do wytwarzania leku |
IL144900A (en) | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
US6703412B1 (en) | 2002-09-27 | 2004-03-09 | Holly A. Rosenthal | Method of treating sleeplessness with melatonin on an acute basis |
JP2014533981A (ja) | 2011-09-27 | 2014-12-18 | アイビス・メディカル・インコーポレーテッド | 胃内インプラントデバイス |
-
2001
- 2001-08-14 IL IL144900A patent/IL144900A/en active IP Right Grant
-
2002
- 2002-07-29 UY UY27401A patent/UY27401A1/es not_active Application Discontinuation
- 2002-07-31 CL CL2002001701A patent/CL2002001701A1/es unknown
- 2002-08-05 AR ARP020102964A patent/AR034975A1/es not_active Application Discontinuation
- 2002-08-08 JO JOP/2002/0086A patent/JO3446B1/ar active
- 2002-08-09 PA PA20028552301A patent/PA8552301A1/es unknown
- 2002-08-12 MX MXPA04001372A patent/MXPA04001372A/es unknown
- 2002-08-12 DK DK16172415.8T patent/DK3103443T3/da active
- 2002-08-12 SI SI200231087T patent/SI1441702T1/sl unknown
- 2002-08-12 EP EP02760523.7A patent/EP1441702B1/en not_active Revoked
- 2002-08-12 KR KR10-2004-7002245A patent/KR20040032917A/ko active Search and Examination
- 2002-08-12 RU RU2011131532/15A patent/RU2560840C2/ru active
- 2002-08-12 ES ES02760523.7T patent/ES2626591T3/es not_active Expired - Lifetime
- 2002-08-12 PT PT2760523T patent/PT1441702T/pt unknown
- 2002-08-12 CA CA2454699A patent/CA2454699C/en not_active Expired - Lifetime
- 2002-08-12 ES ES16172415T patent/ES2882584T3/es not_active Expired - Lifetime
- 2002-08-12 PT PT161724158T patent/PT3103443T/pt unknown
- 2002-08-12 EP EP16172415.8A patent/EP3103443B1/en not_active Expired - Lifetime
- 2002-08-12 HU HU0401042A patent/HU230786B1/hu unknown
- 2002-08-12 WO PCT/IL2002/000662 patent/WO2003015690A2/en active Application Filing
- 2002-08-12 BR BR0211855-6A patent/BR0211855A/pt not_active Application Discontinuation
- 2002-08-12 AU AU2002326114A patent/AU2002326114C1/en not_active Expired
- 2002-08-12 CN CNB028158326A patent/CN100453078C/zh not_active Ceased
- 2002-08-12 LT LTEP02760523.7T patent/LT1441702T/lt unknown
- 2002-08-12 NZ NZ531318A patent/NZ531318A/en not_active IP Right Cessation
- 2002-08-12 PL PL02367872A patent/PL367872A1/xx not_active Application Discontinuation
- 2002-08-12 EA EA200400302A patent/EA200400302A1/ru unknown
- 2002-08-12 US US10/486,688 patent/US8962024B2/en active Active
- 2002-08-12 JP JP2003520451A patent/JP2005501095A/ja active Pending
- 2002-08-12 IS IS7136A patent/IS3004B/is unknown
- 2002-08-12 DK DK02760523.7T patent/DK1441702T3/en active
- 2002-08-13 GT GT200200164A patent/GT200200164A/es unknown
- 2002-08-13 PE PE2002000731A patent/PE20030331A1/es not_active Application Discontinuation
- 2002-12-08 UA UA2004031856A patent/UA87262C2/ru unknown
-
2004
- 2004-01-09 NO NO20040087A patent/NO334788B2/no not_active IP Right Cessation
- 2004-03-03 CR CR7271A patent/CR7271A/es unknown
- 2004-03-12 ZA ZA2004/02005A patent/ZA200402005B/en unknown
- 2004-11-15 HK HK04109022.9A patent/HK1066161A1/xx not_active IP Right Cessation
-
2017
- 2017-05-31 CY CY20171100561T patent/CY1118924T1/el unknown
-
2021
- 2021-08-31 CY CY20211100776T patent/CY1124763T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018127821A (ru) | Применение производного рапамицина | |
RU2011131532A (ru) | Способ лечения бессонницы | |
ITRM920155A1 (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
RU2002126615A (ru) | Рецептуры ранолазина пролонгированного действия | |
PE20040751A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
AR045630A1 (es) | Formas de dosificacion de azitromicina con efectos secundarios reducidos | |
EA200400007A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ | |
RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
RU2002100254A (ru) | Анестетическая композиция, включающая антагонист nmda b альфа-2 адренергический агонист | |
RU97119427A (ru) | Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом | |
CA2563058A1 (en) | Supportive treatment of liver disease | |
WO2002009702A3 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
RU2006113366A (ru) | Терапевтическое лечение | |
RU2005105302A (ru) | Композиция бицифадина | |
RU2002124141A (ru) | Применение миртазапина для лечения расстройств сна | |
EA200501223A1 (ru) | Терапевтическая система, содержащая амоксициллин и клавулановую кислоту | |
GEP201606538B (en) | Preoperative treatment of post operative pain | |
RU2209064C2 (ru) | Новое применение в медицинских целях | |
RU2005135649A (ru) | Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги | |
UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
RU98101105A (ru) | Новое применение в медицинских целях | |
RU2003104017A (ru) | Ингибиторы тромбина, содержащие аминоизохинолиновую группу |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HE9A | Changing address for correspondence with an applicant |